Search
  • EPA-Insight

Auris Medical Holding (EARS),Granted Allowance for U.S. and European Patent Applications

Auris Medical Holding (EARS),Granted Allowance for U.S. and European Patent Applications Covering Intranasal


Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application entitled “Pharmaceutical Composition Comprising Betahistine” (U.S. Patent Application No. 15/887,388).


In addition, the Company received an “Intention to Grant” notice from the European Patent Office (EPO) for its related patent application entitled “Intranasal Composition Comprising Betahistine” (European Patent Application 18 703 749.4). Upon issuance, the patents are expected to expire no earlier than February 2038 and will provide key intellectual property protection for the Company's intranasal betahistine program.



The allowed claims cover composition of matter and methods of use for formulations of betahistine dihydrochloride for intranasal delivery. The communications from the USPTO and EPO conclude substantive examination of the patent applications, which are now expected to issue as patents once the issue fees are paid and the patent offices conclude their respective administrative procedures. Auris Medical also has filed corresponding patent applications that will allow the Company to seek similar patent protection in other key markets throughout the world.


“We are very pleased to have achieved this major milestone in the protection of our intellectual property around the intranasal betahistine program“, commented Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “The intranasal delivery route allows for a surprisingly strong increase in betahistine concentration in the bloodstream compared to the common oral route, which is expected to result in superior therapeutic benefits. We look forward to developing this innovation further in order to help patients who are suffering from vertigo or antipsychotic-induced weight gain, among other potential medical conditions.”


Source - https://ir.aurismedical.com/news-releases/news-release-details/auris-medical-announces-notices-allowance-us-and-european-patent

0 views

© 2019 by EPA-Insight

Follow Us

  • Grey Facebook Icon
  • Grey Twitter Icon
  • Grey LinkedIn Icon
  • Grey YouTube Icon